Výsledky vyhledávání - "Sarah Mische"

Akademický článek

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Autor: Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey

Publikováno v: BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-13 (2022)

Abstract Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to

Externí odkaz: https://doaj.org/article/2b6ddb482f4647ea80752eeb69327c09

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Motility screen identifies Drosophila IGF-II mRNA-binding protein--zipcode-binding protein acting in oogenesis and synaptogenesis.

Autor: Kristin L M Boylan, Sarah Mische, Mingang Li, Guillermo Marqués, Xavier Morin, William Chia, Thomas S Hays

Publikováno v: PLoS Genetics, Vol 4, Iss 2, p e36 (2008)

The localization of specific mRNAs can establish local protein gradients that generate and control the development of cellular asymmetries. While all evidence underscores the importance of the cytoskeleton in the transport and localization of RNAs, w

Externí odkaz: https://doaj.org/article/af014414f40b4297bda266c958c007fa

Zobrazit plný text záznamu

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Autor: Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey

Publikováno v: BMC infectious diseases. 22(1)

Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e9450a49b429007f1f256874c3976d1
https://pubmed.ncbi.nlm.nih.gov/35279084

Zobrazit plný text záznamu

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660

Autor: Sarah Klein, Kenneth F. Blount, Sarah Mische, Heidi Hau

Publikováno v: Open Forum Infectious Diseases

Background Vancomycin-resistant Enterococcus (VRE) infection is frequently associated with immunocompromised and critically ill patients. VRE carriers are at increased risk for infection due to VRE colonization and they pose a risk as a transmission

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e131f32f7169c7af5b4d3542201782f5
https://doi.org/10.1093/ofid/ofz360.738

Zobrazit plný text záznamu

Plný text ve formátu HTML

LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections

Autor: Robert Orenstein, Sarah Mische, Ken Blount, Lindy Bancke, Xin Su, Dana Walsh, Adam Harvey, Carlos Gonzalez, Dale N Gerding

Publikováno v: Open Forum Infectious Diseases

Background Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat associated with significant mortality and medical cost. Microbiota therapy is gaining acceptance as a strategy to reduce rCDI recurrence. We present the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761900e54cc3b613ad9a6f2965bad831
http://europepmc.org/articles/PMC6810069

Zobrazit plný text záznamu

Plný text ve formátu HTML

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study

Autor: Gail Hecht, Herbert Dupont, Sahil Khanna, Robert Orenstein, Christine H. Lee, Erik R. Dubberke, Kenneth F. Blount, Sarah Mische

Publikováno v: Open Forum Infectious Diseases

Background Numerous microbiota-based therapies are being evaluated for prevention of C. difficile infection (rCDI), a public health threat with high recurrence rates associated with the current standard of care. RBX2660, a standardized microbiota-bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759be72b740e76f3f0b4e9639b1ca06a
https://doi.org/10.1093/ofid/ofy210.1606

Zobrazit plný text záznamu

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection

Autor: Kenneth F. Blount, Sarah Mische, Bill Shannon, Courtney Jones

Publikováno v: Open Forum Infectious Diseases

Background Recurrent Clostridium difficile infections (rCDI) are a public health threat with insufficient treatment options at present. Two Phase 2 clinical studies have reported the efficacy of RBX2660, a standardized, stabilized microbiota-based dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5ac69af85ff19a682f63333d2a4037
https://doi.org/10.1093/ofid/ofz360.737

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání